To investigate whether metformin affects HCC formation in CLI Fah−/− mice (under 2.5% NTBC), the mice were treated with either metformin (Met12) or an equal volume of saline solution (C12) for 12 weeks (Figure 2A). Here, FAH is linked to hepatocellular carcinoma.